Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

EYEGW

Eyegate Pharmaceuticals (EYEGW)

Eyegate Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EYEGW
DateTimeSourceHeadlineSymbolCompany
21/09/201622:30GlobeNewswire Inc.EyeGate Pharmaceuticals to Present at the 2016 Aegis Capital ConferenceNASDAQ:EYEGWEyegate Pharmaceuticals Inc
13/09/201622:30GlobeNewswire Inc.EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of DefenseNASDAQ:EYEGWEyegate Pharmaceuticals Inc
12/09/201622:30GlobeNewswire Inc.EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437NASDAQ:EYEGWEyegate Pharmaceuticals Inc
06/09/201622:30GlobeNewswire Inc.EyeGate Pharmaceuticals to Present at the 18th Annual Rodman and Renshaw Global Investment ConferenceNASDAQ:EYEGWEyegate Pharmaceuticals Inc
11/08/201606:50GlobeNewswire Inc.EyeGate Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business UpdateNASDAQ:EYEGWEyegate Pharmaceuticals Inc
01/08/201622:30GlobeNewswire Inc.EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammat...NASDAQ:EYEGWEyegate Pharmaceuticals Inc
01/07/201603:00GlobeNewswire Inc.EyeGate Announces Completion of $3.77 Million Registered Direct OfferingNASDAQ:EYEGWEyegate Pharmaceuticals Inc
27/06/201622:00GlobeNewswire Inc.EyeGate Announces $3.77 Million Registered Direct OfferingNASDAQ:EYEGWEyegate Pharmaceuticals Inc
01/06/201622:30GlobeNewswire Inc.EyeGate Announces Encouraging Interim Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Ocular Inflammation an...NASDAQ:EYEGWEyegate Pharmaceuticals Inc
25/05/201608:00GlobeNewswire Inc.EyeGate Pharma Announces At The Market Issuance ProgramNASDAQ:EYEGWEyegate Pharmaceuticals Inc
14/05/201607:25GlobeNewswire Inc.Eyegate Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business UpdateNASDAQ:EYEGWEyegate Pharmaceuticals Inc
06/05/201622:30GlobeNewswire Inc.EyeGate Pharma Appoints Dr. Brenda K. Mann as Vice President, Research and DevelopmentNASDAQ:EYEGWEyegate Pharmaceuticals Inc
29/04/201601:46GlobeNewswire Inc.EyeGate Pharma to Present Four Posters at ARVO 2016 Annual Meeting Supporting Development of CMHA-SNASDAQ:EYEGWEyegate Pharmaceuticals Inc
28/04/201606:05GlobeNewswire Inc.EyeGate Pharma Appoints Ryan R. Brenneman as Chief Financial OfficerNASDAQ:EYEGWEyegate Pharmaceuticals Inc
30/03/201607:45GlobeNewswire Inc.EyeGate Reports Full-year 2015 Financial Results and Provides Business UpdateNASDAQ:EYEGWEyegate Pharmaceuticals Inc
10/03/201611:46GlobeNewswire Inc.EyeGate Pharma Acquires Jade TherapeuticsNASDAQ:EYEGWEyegate Pharmaceuticals Inc
10/03/201611:46GlobeNewswire Inc.EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437NASDAQ:EYEGWEyegate Pharmaceuticals Inc
20/01/201600:30GlobeNewswire Inc.EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior UveitisNASDAQ:EYEGWEyegate Pharmaceuticals Inc
15/01/201601:49GlobeNewswire Inc.Eyegate Pharmaceuticals to Present at the Noble Financial Capital Markets’ 12th Annual Investor ConferenceNASDAQ:EYEGWEyegate Pharmaceuticals Inc
13/11/201500:30GlobeNewswire Inc.EyeGate Reports Third Quarter 2015 Financial Results and Provides Business UpdateNASDAQ:EYEGWEyegate Pharmaceuticals Inc
06/11/201500:45GlobeNewswire Inc.EyeGate Announces Interim Data From Phase 1b / 2a Clinical Trial of Iontophoretic EGP-437 Ophthalmic Solution in Macular Edem...NASDAQ:EYEGWEyegate Pharmaceuticals Inc
15/10/201523:30GlobeNewswire Inc.EyeGate Pharma Receives USPTO Notice of Allowance for Next Generation of Proprietary Iontophoretic Delivery SystemNASDAQ:EYEGWEyegate Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:EYEGW